--- title: "Insider Selling: Stephen M Bloch Unloads $14.27M Of Liquidia Stock" type: "News" locale: "en" url: "https://longbridge.com/en/news/289486314.md" description: "Stephen M Bloch, a board member at Liquidia (NASDAQ:LQDA), sold 220,835 shares worth $14.27 million on June 10, as disclosed in an SEC Form 4 filing. Following the transaction, Liquidia's stock rose 6.89% to $69.75. The company reported significant revenue growth but faces challenges with high debt and overvaluation metrics compared to industry peers." datetime: "2026-06-11T15:03:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/289486314.md) - [en](https://longbridge.com/en/news/289486314.md) - [zh-HK](https://longbridge.com/zh-HK/news/289486314.md) --- # Insider Selling: Stephen M Bloch Unloads $14.27M Of Liquidia Stock Revealing a significant insider sell on June 10, **Stephen M Bloch**, Board Member at **Liquidia** (NASDAQ:LQDA), as per the latest SEC filing. **What Happened:** A Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday outlined that Bloch executed a sale of 220,835 shares of **Liquidia** with a total value of $14,273,682. The latest update on Thursday morning shows **Liquidia** shares up by 6.89%, trading at $69.75. ### All You Need to Know About Liquidia Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil. ### Liquidia: Delving into Financials **Positive Revenue Trend:** Examining Liquidia's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of **4158.49%** as of 31 March, 2026, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector. **Holistic Profitability Examination:** - Gross Margin: With a high gross margin of 91.08%, the company demonstrates effective cost control and strong profitability relative to its peers. - Earnings per Share (EPS): Liquidia's EPS is below the industry average. The company faced challenges with a current EPS of 0.6. This suggests a potential decline in earnings. **Debt Management:** Liquidia's debt-to-equity ratio surpasses industry norms, standing at **1.7**. This suggests the company carries a substantial amount of debt, posing potential financial challenges. **Valuation Metrics:** - Price to Earnings (P/E) Ratio: Liquidia's current Price to Earnings (P/E) ratio of 383.65 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment. - Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 20.39 as compared to the industry average, the stock might be considered overvalued based on sales performance. - EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Liquidia's EV/EBITDA ratio of 107.11 exceeds industry averages, indicating a premium valuation in the market **Market Capitalization Analysis:** Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity. ### The Impact of Insider Transactions on Investments Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering. Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction. Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise. Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors. ### Breaking Down the Significance of Transaction Codes Navigating through the landscape of transactions, investors often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A **P** in Box 3 denotes a purchase, while **S** signifies a sale. Transaction code **C** signals the conversion of an option, and transaction code **A** denotes a grant, award, or other acquisition of securities from the company. Check Out The Full List Of Liquidia's Insider Trades. _This article was generated by Benzinga's automated content engine and reviewed by an editor._ ### Related Stocks - [LQDA.US](https://longbridge.com/en/quote/LQDA.US.md) ## Related News & Research - [Major Insider Move at Liquidia Technologies Shakes Up Investor Watchlists](https://longbridge.com/en/news/289405446.md) - [Liquidia added to S&P SmallCap 600 ahead of June 22 trading](https://longbridge.com/en/news/289100240.md) - [A Short Squeeze Is Underway in Cracker Barrel Stock. What to Know.](https://longbridge.com/en/news/289376474.md) - [Sugar Prices Tumble as Crude Oil Plunges](https://longbridge.com/en/news/289217660.md) - [Micron selloff was a ‘buying opportunity’—but the stock continues to fall](https://longbridge.com/en/news/289222277.md)